Market revenue in 2024 | USD 154.2 million |
Market revenue in 2030 | USD 299.6 million |
Growth rate | 11.7% (CAGR from 2025 to 2030) |
Largest segment | Exocrine |
Fastest growing segment | Endocrine |
Historical data covered | 2018 - 2023 |
Base year for estimation | 2024 |
Forecast period covered | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Exocrine, Endocrine |
Key market players worldwide | Accuray Inc, AstraZeneca PLC ADR, Novartis AG ADR, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Ipsen Pharma, Eli Lilly and Co, Siemens Healthineers AG ADR, Elekta AB ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer treatment market will help companies and investors design strategic landscapes.
Exocrine was the largest segment with a revenue share of 88.39% in 2024. Horizon Databook has segmented the Latin America pancreatic cancer treatment market based on exocrine, endocrine covering the revenue growth of each sub-segment from 2018 to 2030.
The pancreatic cancer treatment market in Latin America is growing rapidly, driven by increasing awareness of the disease and expanding access to advanced treatment options. Latin America saw a rising number of pancreatic cancer cases, particularly in countries such as Brazil and Mexico.
Where the incidence has been steadily climbing due to aging populations and improved diagnostic capabilities. Global pharmaceutical companies have been expanding their presence in the region by focusing on both immunotherapy and targeted therapies.
For instance, AstraZeneca, has been conducting clinical trials of its immunotherapy treatments, with promising early-phase results from patients in Brazil. Novartis AG has made strides in promoting personalized medicine and molecular profiling for pancreatic cancer, which is gaining traction in major oncology centers across Latin America.
Horizon Databook provides a detailed overview of continent-level data and insights on the Latin America pancreatic cancer treatment market , including forecasts for subscribers. This continent databook contains high-level insights into Latin America pancreatic cancer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account